Vitiligo

Vitiligo
Classification and external resources

Non-Segmental Vitiligo of the hand in a dark-skinned individual
ICD-10 L80
ICD-9 709.01
OMIM 193200
DiseasesDB 13965
MedlinePlus 000831
eMedicine derm/453
MeSH D014820

Vitiligo ( /ˌvɪtɨˈlɡ/) is a condition that causes depigmentation of sections of skin. It occurs when melanocytes, the cells responsible for skin pigmentation, die or are unable to function. The cause of vitiligo is unknown, but research suggests that it may arise from autoimmune, genetic, oxidative stress, neural, or viral causes.[1] The incidence worldwide is less than 1%.[2] The most common form is non-segmental vitiligo, which tends to appear in symmetric patches, sometimes over large areas of the body.

Contents

Signs and symptoms

The most notable symptom of vitiligo is depigmentation of patches of skin that occurs on the extremities.[3][4] Although patches are initially small, they often enlarge and change shape.[1][3] When skin lesions occur, they are most prominent on the face, hands and wrists.[3][4] Depigmentation is particularly noticeable around body orifices, such as the mouth, eyes, nostrils, genitalia and umbilicus.[3][4] Some lesions have hyperpigmentation around the edges.[5] Patients who are stigmatised for their condition may experience depression and similar mood disorders.[6]

Treatment

There are a number of treatments that treat vitiligo. Treatment options generally fall into four groups:[7]

UVB phototherapy

Exposing the skin to UVB light from UVB lamps is the most common treatment for vitiligo.

The treatments can be done at home with a domestic UVB lamp or in a clinic. Normally a small lamp is needed if the spot is small.

Treatment can take a few weeks if the spots are on the neck and face and if they existed not more than 3 years. If the spots are on the hands and legs and have been there more than 3 years, it can take a few months.

In a clinic the treatments are done 2-3 times a week, and at home every day, which makes the home treatments more effective.

If the spots are on a large area of the body, full body treatment in a clinic or hospital will be needed.

Both UVB Broadband and UVB Narrowband lamps can be used.

Narrow-band ultraviolet B is a useful and well-tolerated treatment for vitiligo.

Treatment of vitiligo Treatment of vitiligo with broadband ultraviolet B and vitamin

Adding a Psoralen, a material that increases the effect of the UV light, can speed the cure, especially if the spots are on the hands or legs, where the cure can take several months.

Studies have shown that immunomodulator creams such as Protopic and Elidel also cause repigmentation in some cases, when used with UVB narrowband treatments.[8][9]

A 1997 report[10] suggests that combining Vitamin B12 and folic acid supplements with sun exposure caused repigmentation in 52% of cases.

PUVA phototherapy

Ultraviolet light (UVA) treatments are normally carried out in a hospital clinic. Psoralen and Ultraviolet A light (PUVA) treatment involves taking a drug which increases the skin's sensitivity to ultraviolet light. The skin is then exposed to high doses of ultraviolet A light (UVA). Treatment is required twice a week for 6–12 months or longer. Because of the high doses of UVA and the Psoralen, PUVA may cause side effects such as 'sunburn' type reactions or skin freckling.[7]

Narrowband ultraviolet B (UVB) phototherapy is now used more commonly than PUVA as it is less damaging to the skin. As with PUVA, treatment is carried out twice weekly in a clinic or every day at home, and there is no need to use a Psoralen.[7]

A few preliminary trials have been carried out using the herb ginkgo biloba. A small scale open label pilot clinical trial found the progression of vitiligo stopped in all participants; the total VASI (Vitiligo Area Scoring Index) indicated an average repigmentation of vitiligo lesions of 15%. The authors conclude "Larger, randomized double-blind clinical studies are warranted and appear feasible." [11]

Transplanting melanocytes

In October 1992, a scientific report was published of successfully transplanting melanocytes to vitiligo affected areas, effectively repigmenting the region.[12] The procedure involved taking a thin layer of pigmented skin from the patient's gluteal region. Melanocytes were then separated out to a cellular suspension that was expanded in culture. The area to be treated was then denuded with a dermabrader and the melanocytes graft applied. Between 70 and 85 percent of patients experienced nearly complete repigmentation of their skin. The longevity of the repigmentation differed from person to person.[13] Today the methods are in clinical practice and specialised centers such as International Vitiligo Center that helps patients from all over the world.

Skin camouflage

In mild cases, vitiligo patches can be hidden with makeup or other cosmetic camouflage solutions. If the affected person is pale-skinned, the patches can be made less visible by avoiding sunlight and sun tanning of unaffected skin.[14]

Reversal

The traditional treatment is the application of corticosteroid cream.[15]

De-pigmenting

In cases of extensive vitiligo the option to de-pigment the unaffected skin with topical drugs like monobenzone, mequinol or hydroquinone may be considered to render the skin an even colour. The removal of all the skin pigment with monobenzone is permanent and vigorous sun-safety must be adhered to for life to avoid severe sun burn and melanomas. Depigmentation takes about a year to complete.[7]

Non-segmental

In non-segmental vitiligo (NSV), there is usually some form of symmetry in the location of the patches of depigmentation. New patches also appear over time and can be generalized over large portions of the body or localized to a particular area. Vitiligo where little pigmented skin remains is referred to as vitiligo universalis. NSV can come about at any age, unlike segmental vitiligo, which is far more prevalent in teenage years.[5]

Classes of non-segmental Vitiligo include:

Segmental

Segmental vitiligo (SV) differs in appearance, etiology and prevalence from associated illnesses. Its treatment is different from that of NSV. It tends to affect areas of skin that are associated with dorsal roots from the spine and is most often unilateral. It spreads much more rapidly than NSV and, without treatment, it is much more stable/ static in course and it is associated with auto-immune diseases and a very treatable condition that responds to topical treatment.[5]

Differential diagnosis

Conditions with similar symptoms include:

Pathogenesis

Vitiligo is a disorder characterized by patchy loss of skin pigmentation due to immune attacks on melanocytes. While there is no significant proof or evidence for this, many doctors believe that it can be caused by defects in many genes. Variations in genes that are part of the immune system or part of melanocytes have both been associated with vitiligo. The immune system genes are associated with other autoimmune disorders.

In one case, the gene TYR, which makes the melanocyte more susceptible to the immune system in vitiligo, also makes the melanocyte more susceptible to the immune system in the skin cancer malignant melanoma. So people with vitiligo caused by the TYR gene are less likely to have malignant melanoma.

A genomewide association study found 10 independent susceptibility loci for generalized vitiligo, responsible for 7.4% of the genetic risk. Some patients had vitiligo alone; others had generalized vitiligo with other autoimmune diseases. Most loci were associated with both forms. (The exception was PTPN22, which was only associated with generalized vitiligo.) In the MHC region, which controls the immune system, major association signals were identified in the class I gene region (between HLA-A and HLA-HGC9) and class II gene region (between HLA-DRB1 and HLA-DQA1). Outside the MHC region, association signals were identified near RERE, PTPN22, LPP, IL2RA, GZMB, UBASH3A and C1QTNF6 genes, which are associated with other autoimmune diseases. TYR encodes tyrosinase, which is not a component of the immune system, but is an enzyme of the melanocyte that catalyzes melanin biosynthesis, and a major autoantigen in generalized vitiligo. The major alleles of TYR are associated with vitiligo, and the minor alleles are associated with malignant melanoma. Vitiligo-associated 402R tyrosinase may be more efficiently presented to the immune system. Melanoma-associated 402Q may fail to be identified by the immune system.[16]

The transcriptional profile of melanocytes from vitiligo patients have been studied. Oligonucleotide microarrays containing approximately 16,000 unique genes were used to analyse mRNA expression in melanocytes from vitiligo patients and age-matched healthy controls. In total, 859 genes were identified as differentially expressed.[17]

Vitiligo is sometimes associated with autoimmune and inflammatory diseases,[18] commonly thyroid overexpression and underexpression. A study comparing 656 people with and without vitiligo in 114 families found several mutations (single-nucleotide polymorphisms) in the NALP1 gene.The NALP1 gene, which is on chromosome 17 located at 17p13, is on a cascade that regulates inflammation and cell death, including myeloid and lymphoid cells, which are white cells that are part of the immune response. NALP1 is expressed at high levels in T cells and Langerhan cells, white blood cells that are involved in skin autoimmunity. Polymorphisms of CD4 were shown to be associated with the vitiligo and other autoimmune diseases like type I Diabetes Mellitus.[19]

Among the inflammatory products of NALP1 are caspase 1 and caspase 5, which activate the inflammatory cytokine interleukin-1β. Interleukin-1β is expressed at high levels in patients with vitiligo. There are compounds which inhibit caspase and interleukin-1β, and so might be useful drugs for vitiligo and associated autoimmune diseases. In one of the mutations, the amino acid leucine in the NALP1 protein was replaced by histidine (Leu155->His). The original protein and sequence is highly conserved in evolution, and found in humans, chimpanzee, rhesus monkey, and bush baby, which means that it is an important protein and an alteration is likely to be harmful. Addison's disease (typically an autoimmune destruction of the adrenal glands) may cause vitiligo.[20][21]

Notable cases

See also

References

  1. ^ a b Halder, RM; Chappell, JL (2009). "Vitiligo update.". Seminars in cutaneous medicine and surgery 28 (2): 86–92. doi:10.1016/j.sder.2009.04.008. PMID 19608058. 
  2. ^ Nath SK, Majumder PP, Nordlund JJ (November 1994). "Genetic epidemiology of vitiligo: multilocus recessivity cross-validated". American Journal of Human Genetics 55 (5): 981–90. PMC 1918341. PMID 7977362. http://www.pubmedcentral.nih.gov/articlerender.fcgi?tool=pmcentrez&artid=1918341. 
  3. ^ a b c d National Institute of Arthritis and Musculoskeletal and Skin Diseases (March 2007). "What Is Vitiligo? Fast Facts: An Easy-to-Read Series of Publications for the Public Additional". http://www.niams.nih.gov/Health_Info/Vitiligo/vitiligo_ff.asp#c. Retrieved July 18, 2010. 
  4. ^ a b c Halder RM, et al. (2007). "72. Vitiligo". In Wolff K, Freedberg IM, Fitzpatrick TB (eds). Fitzpatrick's dermatology in general medicine (7th ed.). New York: McGraw-Hill Professional. ISBN 9780071466905. OCLC 154751587. 
  5. ^ a b c Huggins RH, Schwartz RA, Janniger CK (December 2005). "Vitiligo". Acta Dermatovenerologica Alpina, Panonica, et Adriatica 14 (4): 137–42, 144–5. PMID 16435042. http://www.mf.uni-lj.si/acta-apa/acta-apa-05-4/2.pdf. 
  6. ^ Picardi A, Pasquini P, Cattaruzza MS, Gaetano P, Melchi CF, Baliva G, Camaioni D, Tiago A, Abeni D, Biondi M (2003). "Stressful life events, social support, attachment security and alexithymia in vitiligo. A case-control study". Psychotherapy and Psychosomatics 72 (3): 150–8. doi:10.1159/000069731. PMID 12707482. 
  7. ^ a b c d Anon. "What are the treatment options for vitiligo?". Patient UK. EMIS & PiP. http://www.patient.co.uk/health/Vitiligo.htm. Retrieved 1 February 2010. 
  8. ^ Tanghetti EA (February 2003). "Tacrolimus ointment 0.1% produces repigmentation in patients with vitiligo: results of a prospective patient series". Cutis 71 (2): 158–62. PMID 12635898. 
  9. ^ Silverberg NB, Lin P, Travis L, et al. (November 2004). "Tacrolimus ointment promotes repigmentation of vitiligo in children: a review of 57 cases". Journal of the American Academy of Dermatology 51 (5): 760–6. doi:10.1016/j.jaad.2004.05.036. PMID 15523355. 
  10. ^ Juhlin L, Olsson MJ (November 1997). "Improvement of vitiligo after oral treatment with vitamin B12 and folic acid and the importance of sun exposure". Acta Derm. Venereol. 77 (6): 460–2. PMID 9394983. 
  11. ^ Szczurko, O; Shear N, Taddio A, Boon H (15). "Ginkgo biloba for the treatment of Vitiligo vulgaris: an Open Label Pilot Clinical Trial". BMC Complementary and Alternative Medicine 11: 21. doi:10.1186/1472-6882-11-21. http://www.biomedcentral.com/1472-6882/11/21/abstract. Retrieved 16 March 2011. 
  12. ^ Olsson MJ, Juhlin L (October 1992). "Melanocyte transplantation in vitiligo". Lancet 340 (8825): 981. doi:10.1016/0140-6736(92)92875-G. PMID 1357390. 
  13. ^ Olsson MJ, Juhlin L (November 2002). "Long-term follow-up of leucoderma patients treated with transplants of autologous cultured melanocytes, ultrathin epidermal sheets and basal cell layer suspension". The British Journal of Dermatology 147 (5): 893–904. doi:10.1046/j.1365-2133.2002.04837.x. PMID 12410698. 
  14. ^ a b c d e f g h i j Halder RM, et al. Vitiligo. In: Wolff K, et al. Fitzpatrick's Dermatology in General Medicine. 7th ed. New York, N.Y.: McGraw-Hill Professional; 2007
  15. ^ Kwinter J, Pelletier J, Khambalia A, Pope E (February 2007). "High-potency steroid use in children with vitiligo: a retrospective study". Journal of the American Academy of Dermatology 56 (2): 236–41. doi:10.1016/j.jaad.2006.08.017. PMID 17224367. 
  16. ^ Jin Y, Birlea SA, Fain PR, et al. (May 2010). "Variant of TYR and Autoimmunity Susceptibility Loci in Generalized Vitiligo". N. Engl. J. Med. 362 (18): 1686–97. doi:10.1056/NEJMoa0908547. PMC 2891985. PMID 20410501. http://content.nejm.org/cgi/pmidlookup?view=short&pmid=20410501&promo=ONFLNS19. 
  17. ^ Strömberg S, Björklund MG, Asplund A, et al. (April 2008). "Transcriptional profiling of melanocytes from patients with vitiligo vulgaris". Pigment Cell & Melanoma Research 21 (2): 162–71. doi:10.1111/j.1755-148X.2007.00429.x. PMID 18426409. 
  18. ^ Hedstrand H, Ekwall O, Olsson MJ, et al. (September 2001). "The transcription factors SOX9 and SOX10 are vitiligo autoantigens in autoimmune polyendocrine syndrome type I". The Journal of Biological Chemistry 276 (38): 35390–5. doi:10.1074/jbc.M102391200. PMID 11423552. 
  19. ^ Mashaghi A et al. Possible association of the CD4 gene polymorphism with vitiligo. Clin Exp Dermatol. (2010) 35(5):521-4. link
  20. ^ Gregersen PK (March 2007). "Modern genetics, ancient defenses, and potential therapies". The New England Journal of Medicine 356 (12): 1263–6. doi:10.1056/NEJMe078017. PMID 17377166. 
  21. ^ Jin Y, Mailloux CM, Gowan K, et al. (March 2007). "NALP1 in vitiligo-associated multiple autoimmune disease". The New England Journal of Medicine 356 (12): 1216–25. doi:10.1056/NEJMoa061592. PMID 17377159. 
  22. ^ Original by Alan Light
  23. ^ Pathania, Amit (7 november 2009). "Michael Jackson's Glove Hid Skin Problem". Top News. http://topnews.us/content/26135-michael-jacksons-glove-hid-skin-problem. Retrieved 1 February 2010. 
  24. ^ Siemaszko, Corky (2010-02-10). "Michael Jackson autopsy report confirms singer suffered from vitiligo, wore wig, had tattooed makeup". New York Daily News. http://www.nydailynews.com/gossip/2010/02/10/2010-02-10_michael_jackson_autopsy_report_confirms_singer_suffered_from_vitiligo_wore_wig_h.html. 
  25. ^ "Vitiligo: Michael Jackson Autopsy Confirms Skin Disorder". Nowpublic.com. http://www.nowpublic.com/culture/vitiligo-michael-jackson-autopsy-confirms-skin-disorder-2572670.html. Retrieved 2011-01-31. 
  26. ^ "Michael Jackson Deposition 1996". YouTube. http://www.youtube.com/watch?v=g3u_HyCis4Y. Retrieved 2011-01-31. 
  27. ^ Barber, Lynn (2001-10-28). "Glad to be Graham". The Guardian (London). http://observer.guardian.co.uk/life/story/0,,582020,00.html. Retrieved 2010-04-09. 
  28. ^ 'I'm a black man turning white on television'", BrisbaneTimes, December 18, 2007
  29. ^ "Turning White". Turning White. http://www.turningwhite.com/. Retrieved 2011-01-31. 
  30. ^ "FOX TV Reporter Refuses to Give In to Skin Disorder Turning Him White". Associated Press. Fox News Channel. 2007-12-17. http://www.foxnews.com/story/0,2933,317065,00.html. Retrieved 2009-02-09. "'I'm a black man turning white on television and people can see it,' says Thomas, an anchor and entertainment reporter for the local Fox Broadcasting Company affiliate. 'If you've watched me over the years, you've seen my hands completely change from brown to white.'" 
  31. ^ Baxter, Biddy; Barnes, Edward (1989). "9. Crest of a Wave". Blue Peter: The Inside Story. Letchworth: Ringpress. pp. 214–216. ISBN 0-948955-50-3. 
  32. ^ Epstein, Angela; Fielding, Yvette (6 May 2003). "My skin colour changed from dark olive to a bleach white". Daily Mail (London: Associated Newspapers): p. 39. ISSN 0307-7578. 
  33. ^ Atkinson, Jim (1996-03-01). "Pale by Comparison". Texas Monthly. http://www.texasmonthly.com/preview/1996-03-01/health. Retrieved 2011-01-31. 
  34. ^ "Famous People Vitiligo". Vitiligos.com. 2010-02-12. http://www.vitiligos.com/people-with-vitiligo/famous-people/. Retrieved 2011-01-31. 
  35. ^ "Scott Jorgensen talks about rare skin condition". Fiveknuckles.com. http://www.fiveknuckles.com/mma-news/Scott-Jorgensen-talks-about-rare-skin-condition.html. Retrieved 2011-01-31. 
  36. ^ "Daniel Bryan tweets about his skin condition". Twitter.com. http://twitter.com/#!/WWEDanielBryan/status/97214858474422272. Retrieved 2011-07-29. 
  37. ^ "Mad Men star's stress disease". The Age (Melbourne). 2010-09-06. http://www.theage.com.au/lifestyle/people/mad-men-stars-stress-disease-20100906-14xh2.html. 
  38. ^ http://www.vitiligoguide.com/famous-people/john-henson/

External links

Vitiligo Treatment | Uv Therapy